IMMUXELL BIOTECH LTD.

Primary objective: To evaluate the safety and tolerability of IX001 TCR-T injection in patients with advanced pancreatic cancer with KRAS G12V mutation. Secondary objectives: 1) To evaluate the preliminary efficacy of IX001 TCR-T injection in patients with advanced pancreatic cancer with KRAS G12V mutation; 2) To evaluate the proliferation and survival of IX001 TCR-T injection in patients; 3) To evaluate the changes in cytokines and lymphocyte subtypes after infusion of IX001 TCR-T injection; 4) To evaluate the immunogenicity of TCR produced by the human body after infusion of IX001 TCR-T injection; 5) To detect the replication-competent retrovirus (RCR) in the human body after infusion of IX001 TCR-T injection; 6) To evaluate the risk of viral insertion sites in the human body after infusion of IX001 TCR-T injection.